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Abstract
Background: Topical negative pressure (TNP), commonly used in wound therapy, has been
shown to increase blood flow and stimulate angiogenesis in skeletal muscle. We have previously
shown that a myocardial TNP of -50 mmHg significantly increases microvascular blood flow in the
myocardium. When TPN is used in wound therapy (on skeletal and subcutaneous tissue) a zone of
relative hypoperfusion is seen close to the wound edge. Hypoperfusion induced by TNP is thought
to depend on tissue density, distance from the negative pressure source, and the amount negative
pressure applied. When applying TNP to the myocardium, a significant, long-standing zone of
hypoperfusion could theoretically cause ischemia, and negative effects on the myocardium. The
current study was designed to elucidate whether hypoperfusion was produced during myocardial
TNP.
Methods:  Six pigs underwent median sternotomy. Laser Doppler probes were inserted
horizontally into the heart muscle in the LAD area, at depths of approximately, 1–2 mm. The
microvascular blood flow was measured before and after the application of a TNP. Analyses were
performed before left anterior descending artery (LAD) occlusion (normal myocardium) and after
20 minutes of LAD occlusion (ischemic myocardium).
Results: A TNP of -50 mmHg induced a significant increase in microvascular blood flow in normal
myocardium (**p = 0.01), while -125 mmHg did not significantly alter the microvascular blood flow.
In ischemic myocardium a TNP of -50 mmHg induced a significant increase in microvascular blood
flow (*p = 0.04), while -125 mmHg did not significantly alter the microvascular blood flow.
Conclusion: No hypoperfusion could be observed in the epicardium in neither normal nor
ischemic myocardium during myocardial TNP.
Introduction
Vacuum therapy, or topical negative pressure (TNP), can
be regarded as an established clinical routine for wound
care, in use since the mid or late 1990's, and it has been
shown to promote the healing of chronic and problematic
wounds [1-3], for example, post-sternotomy mediastini-
tis[4,5]. The physiological and molecular biological
mechanisms by which TNP accelerates wound healing are
to a large extent unknown. However, TNP is known to
increase the blood flow as a result of mechanical stress
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and a pressure gradient across the tissue, and increased
blood flow is known to stimulate granulation tissue for-
mation, and angiogenesis in subcutaneous tissue and
skeletal muscle [6-10].
Mediastinitis is a strong predictor for poor long-term sur-
vival after coronary artery by-pass grafting (CABG), when
using conventional wound healing techniques (closed
irrigation, delayed wound closure, or reconstructing with
omentum or pectoral flaps) [11-16]. Recently, the use of
TNP has gained acceptance in the treatment of post-ster-
notomy mediastinitis, and is today the standard mode of
treatment in many cardiac surgery centers [4,5,17,18].
Previously, we have showed no difference in long-term
survival between CABG patients with TNP-treated medias-
tinitis and CABG patients without mediastinitis [17]. It
may be that the TNP stimulation of blood flow and devel-
opment of collateral blood vessels in part account for the
reduced long-term mortality.
Patients with ungraftable coronary disease may benefit
from methods that increase blood flow to the area and
stimulate myocardial angiogenesis that are not dependent
on vessel caliber. Vascular endothelial growth factor
(VEGF) has been found to be one of the most interesting
growth factors in therapeutic angiogenesis [19-24]. Inter-
estingly, the mechanical forces exerted by TNP stimulate
the endogenous production of VEGF[25,26].
We have previously shown that a myocardial TNP of -50
mmHg significantly increases microvascular blood flow
in the underlying myocardium at a depth of 6–8 mm in
porcine myocardium[27]. We have also shown that TNP
produces relative hypoperfusion close to the wound edge
in muscular and subcutaneous tissue[8]. Hypoperfusion
in myocardial TNP could theoretically lead to ischemia,
with negative consequences in the myocardium. The
present study was designed to elucidate whether a relative
hypoperfusion zone is produced in the epicardium, at a
depth of 1–2 mm in the heart muscle, during the applica-
tion of TNP.
The microvascular blood flow was measured using laser
Doppler velocimetry in a porcine model. The effect of a
TNP of -50 and -125 mmHg was investigated before and
during occlusion of the left anterior descending artery
(LAD) to imitate ischemic coronary disease. No such
study has to our knowledge been performed previously.
Methods
Experimental animals
A porcine model was use in the present study. Six domes-
tic landrace pigs of both genders, with a mean body
weight of 70 kg, were fasted overnight with free access to
water. The study was approved by the Ethics Committee
for Animal Research, Lund University, Sweden. The inves-
tigation complied with the "Guide for the Care and Use of
Laboratory Animals" as recommended by the U.S.
National Institutes of Health, and published by the
National Academies Press (1996).
Anesthesia
All animals were pre-medicated intramuscularly with ket-
amine (30 mg/kg) before they were brought into the lab-
oratory. Before commencing surgery sodium thiopental
(5 mg/kg), atropine (0.02 mg/kg) and pancuronium (0.5
mg/kg) were given intravenously. Tracheotomy was per-
formed with a Portex endo-tracheal tube (7.5 mm internal
diameter, Medcompare™, USA). A servo-ventilator (Sie-
mens Elema 300A, Stockholm, Sweden) was used for
mechanical ventilation throughout the experiment. The
ventilator settings used were: minute volume = 100 ml/kg,
FiO2 = 0.5, breathing frequency = 16 breaths/minute and
positive end expiratory pressure = 5 cmH2O.
Anesthesia and muscular paralysis were maintained with
a continuous intravenous infusion of 8–10 mg/kg/hour
propofol (Diprivan®, AstraZeneca, Sweden), 0.15 mg/kg/
hour fentanyl (Leptanal®, Lilly, France), and 0.6 mg/kg/
hour pancuronium (Pavulon®, Organon Teknika, Boxtel,
the Netherlands).
Data acquisition
Mean arterial pressure, central venous pressure, heart fre-
quency, and ventilatory parameters were recorded
throughout the experiments.
Surgical procedure
Surgery was performed through median sternotomy. After
heparinization (400 IU/kg) a cardiopulmonary bypass
(CPB) was installed with an arterial cannula (22 French,
DLP  ® Elongated One-Piece Arterial Cannula (EOPA™),
Medtronic Inc., Minneapolis, MO, USA) in the distal
ascending aorta, and a venous cannula (32 French, MC2®
Two-Stage Venous Cannula, also from Medtronic Inc.)
inserted through the right atrium. Before cannulation of
the heart the cannulae were inserted through the thoracic
wall to prevent air leakage during TNP application. CPB
was conducted in normothermia. Ventricular fibrillation
was subsequently induced in the heart. No aortic cross-
clamping was performed and no cardioplegia was
employed. The mean arterial pressure was maintained
between 60 and 80 mmHg. A left ventricular vent (DLP®
Vent, also from Medtronic Inc.) was used to protect the
left chamber from overloading. Pulmonary ventilation
was applied at a rate of 4 liters/minute during the experi-
ments.Journal of Cardiothoracic Surgery 2007, 2:53 http://www.cardiothoracicsurgery.org/content/2/1/53
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A CPB was used to facilitate the measurements of microv-
ascular blood flow using laser Doppler velocimetry. Fibril-
lation of the heart minimizes the movement artifacts,
while the physiological conditions are, to a large extent,
conserved. Moreover, CPB prevents the risk of circulatory
failure during LAD occlusion, thereby facilitating experi-
mental analysis in the case of the ischemic myocardium.
Microvascular blood flow was measured using laser Dop-
pler velocimetry (Transonic®  Laser Doppler Monitor,
BLF21, Maastricht, the Netherlands, and Peri Flux System
5000, Perimed, Stockholm, Sweden), employing atech-
nique that quantifies the sum of the motion of the red
blood cells in a specific volume. This method is exten-
sively applied in plastic surgery procedures and employs a
fiberoptic probe carrying a beam of light. Light impinging
on cells in motion undergoes a change in wavelength
(Doppler shift) while light impinging on static objects
remains unchanged. The magnitude and frequency distri-
butions of the changes are directly related to the number
and velocity of red blood cells. The information is col-
lected by a returning fiber, converted into an electronic
signal, and analyzed[28].
Laser Doppler probes were inserted horizontally into the
heart muscle 6–8 mm lateral of the LAD at depths of
approximately 1–2 mm. All probes were carefully fixed to
the surface of the heart with a suture (Prolene 7-0; Ethicon
Inc., New Jersey, USA), thereby preventing probe move-
ment. After the experiments, the heart was dissected and
the probe location was confirmed. A round hole, 5 cm in
diameter, was made in the middle of a phrenic nerve pad
(Phrenic Nerve Pad® Medtronic Inc.) and placed on top of
the heart. The pad was stabilized to the surrounding myo-
cardium by 8–10 sutures (Prolene 5-0; Ethicon Inc., New
Jersey, USA) and by sutures to the posterior sternal edges
(Dermalon 2-0; Davis and Geck, St. Louis, New Jersey,
USA). A retractor was used throughout the experiments to
keep the sternal edges apart. A polyurethane foam dress-
ing, with an open pore structure of 400 to 600 µm (KCI,
Copenhagen, Denmark) was placed between the sternal
edges. The foam was continuously sutured to the sur-
rounding skin (Dermalon 2-0; Davis and Geck). The
wound was sealed with a transparent adhesive drape. A
Track Pad (KCI, Copenhagen, Denmark) was inserted
through the drape and was connected to a vacuum pump,
(V.A.C. pump unit, KCI, Copenhagen, Denmark). When
the negative pressure is applied, the heart will be drawn
up towards the phrenic nerve pad and the foam without
interfering with the sternal edges. This procedure causes
the application of negative pressure to affect only the
myocardium exposed through the 5 cm diameter hole.
Experimental protocol
The microvascular blood flow was measured continu-
ously by the laser Doppler filament probes. Recordings
were made in normal myocardium, before negative pres-
sure was applied, and at negative pressures of -50 and -
125 mmHg.
The LAD was then occluded for 20 minutes with an elastic
vessel loop. Microvascular blood flow was measured
before, and after 5, 10, 15 and 20 minutes of occlusion.
Recordings were also made in ischemic myocardium,
before negative pressure was applied, and at negative pres-
sures of -50 and -125 mmHg.
Calculations and statistics
Laser Doppler velocimetry measurements were performed
on six pigs. The output was continuously recorded using
PeriSoft software (Perimed, Stockholm, Sweden). Microv-
ascular blood flow was expressed in terms of perfusion
units (PU). Calculations and statistical analysis were per-
formed using GraphPad 4.0 software. Statistical analysis
was performed using Student's paired t-test. Significance
was defined as *p < 0.05, **p < 0.01, ***p < 0.001 and p
> 0.05 (not significant, n.s.). Values are presented as
means ± the standard error on the mean (SEM).
Results
Normal myocardium
A topical negative pressure of -50 mmHg induced an
immediate significant increase in microvascular blood
flow in normal myocardium (from 365.8 ± 111.7 PU
before, to 649.8 ± 78.3 PU after TNP application, ** p =
0.01) (Figure 1A). A TNP of -125 mmHg did not result in
any significantly change in microvascular blood flow
(365.8 ± 111.7 PU before, and 279.2 ± 57.1 PU after TNP
application, p = 0.33) (Figure 1B).
LAD occlusion
Ischemia was induced by occlusion of the LAD for 20
minutes. The blood flow was 311.7 ± 106.2 PU before
occlusion of the LAD, and decreased to 90.0 ± 37.3 PU
after 5 minutes (*p = 0.03), to 95.0 ± 32.2 PU after 10
minutes (*p = 0.04), to 95.8 ± 36.9 after 15 minutes (*p =
0.04), and to 84.2 ± 29.9 after 20 minutes (*p = 0.02) of
LAD occlusion (Figure 2).
Ischemic myocardium
A topical negative pressure of -50 mmHg induced an
immediate significant increase in microvascular blood
flow in ischemic myocardium (from 69.0 ± 5.5 PU before,
to 147.0 ± 9.1 PU after TNP application, * p = 0.04) (Fig-
ure 3A). A TNP of -125 mmHg did not result in any signif-
icantly change in microvascular blood flow (69.0 ± 5.5 PU
before, and 75.0 ± 5.9 PU after, p = 0.68) (Figure 3B).Journal of Cardiothoracic Surgery 2007, 2:53 http://www.cardiothoracicsurgery.org/content/2/1/53
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Conclusion
Post-sternotomy mediastinitis after CABG is a serious and
potentially life-threatening complication, with a high
mortality rate and substantial morbidity[12,14,29].
Recently, the use of TNP has gained acceptance in the
treatment of post-sternotomy mediastinitis, and is today
the standard mode of treatment in many cardiac surgery
centers [4,5,17,18]. Before the introduction of TNP ther-
apy, the risk of late death in patients suffering from medi-
astinitis after cardiac surgery was reported to be two to
three times higher than that of patients without medias-
tinitis[12,14,29]. Milano and collages have suggested that
mediastinitis may cause negative long-terms effects on
several organs such as the heart and kidneys [13]. Theoret-
ically, a massive immunological response during a pro-
longed period of infection may cause adverse effects on
by-pass grafts. In those studies, reporting poor long-term
survival after mediastinitis, several conventional wound
healing techniques were used (closed irrigation, delayed
wound closure, or reconstructing with omentum or pecto-
ral flaps). Interestingly, Sjogren and coworkers, found no
difference in long-term survival between CABG patients
with TNP-treated mediastinitis and CABG patients with-
out mediastinitis [17]. During the treatment of post-ster-
notomy mediastinitis, the TNP is in direct contact with the
heart, which is exposed through the diastase of the ster-
notomy. These patients may therefore have developed
increased coronary collateral blood vessels during TNP,
and may be better prepared when bypass grafts fail to
work. We have indeed observed in patients treated with
TNP, that richly vascularized granulation tissue develops
over the heart within 7–8 days. It may well be that the
stimulation of blood flow and the development of collat-
eral blood vessels resulting from TNP in part account for
the reduced long-term mortality in patients treated in this
way.
Microvascular blood flow measured using laser Doppler  velocimetry in ischemic myocardium exposed to topical neg- ative pressures of A) -50 mmHg, and B) -125 mmHg Figure 3
Microvascular blood flow measured using laser Doppler 
velocimetry in ischemic myocardium exposed to topical neg-
ative pressures of A) -50 mmHg, and B) -125 mmHg. The 
measurements were performed in six pigs at a depth at 1–2 
mm in the myocardium. Significance was defined as *p < 0.05, 
**p < 0.01, ***p < 0.001 and p > 0.05 (not significant, n.s.). 
Values are presented as means ± the standard error on the 
mean (SEM).
Microvascular blood flow measured using laser Doppler  velocimetry in normal myocardium exposed to topical nega- tive pressures of A) -50 mmHg, and B) -125 mmHg Figure 1
Microvascular blood flow measured using laser Doppler 
velocimetry in normal myocardium exposed to topical nega-
tive pressures of A) -50 mmHg, and B) -125 mmHg. The 
measurements were performed in six pigs at a depth of 1–2 
mm in the myocardium. Significance was defined as *p < 0.05, 
**p < 0.01, ***p < 0.001 and p > 0.05 (not significant, n.s.). 
Values are presented as means ± the standard error on the 
mean (SEM).
Microvascular blood flow measured using laser Doppler  velocimetry in the myocardium before and after 5, 10, 15,  and 20 minutes of occlusion of the left anterior descending  artery (LAD) Figure 2
Microvascular blood flow measured using laser Doppler 
velocimetry in the myocardium before and after 5, 10, 15, 
and 20 minutes of occlusion of the left anterior descending 
artery (LAD). Note the decrease in microvascular blood 
flow, from 311.7 ± 106.2 PU before, to 84.2 ± 29.9 PU after 
20 minutes' occlusion of the LAD, in the area studied. Signifi-
cance was defined as *p < 0.05, **p < 0.01, ***p < 0.001 and 
p > 0.05 (not significant, n.s.). Values are presented as means 
± the standard error on the mean (SEM).Journal of Cardiothoracic Surgery 2007, 2:53 http://www.cardiothoracicsurgery.org/content/2/1/53
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We have previously shown that TNP induces an increase
in the blood flow of the peristernal soft tissue (i.e. skeletal
muscular and subcutaneous tissue), and also that the
change is related to local effects, since the blood flow at a
distance of 4.5 cm from the wound edge was not affected
by the negative pressure[8]. The blood flow increased with
elevated subatmospheric pressure in both subcutaneous
and skeletal muscular tissue[8]. When the area under the
flow-distance curve was analyzed, covering 0.5 to 4.5 cm
from the wound edge, a maximal net increase in blood
flow was observed at -75 and -100 mmHg, in muscular tis-
sue. Interestingly, a difference in the profiles of the blood
flow responses was observed between the subcutaneous
and the muscular tissue. The distance from the wound
edge to the point at which the blood flow increased was
shorter in muscular tissue than in subcutaneous tissue[8].
This may indicate that pressure is transduced differently in
a soft and in a dense tissue, and a less dense tissue col-
lapses more easily when affected by pressure. In the
immediate proximity of the wound edge, a zone of rela-
tive hypoperfusion was observed. This zone was larger at
high negative pressures and was especially prominent in
subcutaneous tissue. The size of the hypoperfused zone
depended on the pressure applied, and increased with
increasing negative pressure. In summary, the changes in
the peristernal wound blood flow caused by TNP vary
with the distance from the wound edge. A few centimeters
away from the wound edge, the blood flow increased
when subatmospheric pressure was applied. Conversely,
in the immediate proximity of the wound, the negative
pressure induced relative hypoperfusion[8].
We have recently shown that a myocardial TNP of -50
mmHg significantly increases microvascular blood flow
in the underlying myocardium, at a depth of 6–8 mm in
the heart muscle, i.e. the middle of the myocardial ven-
tricular wall, in both normal, ischemic, and reperfused
porcine myocardium[27]. We have also demonstrated
that TNP levels between -75 mmHg and -150 mmHg,
applied to the myocardium, do not alter myocardial
microvascular blood flow, also at depths at 6–8 mm down
into the myocardium[30]. In skeletal muscle and subcuta-
neous tissue, application of different negative pressure
levels causes different changes in microvascular blood
flow[8]. When the negative pressure exceeds a specific
level it seems to constringe the vessels in subcutaneous tis-
sue and skeletal muscle and a decrease in microvascular
blood flow close to the vacuum source, i.e. a zone of
hypoperfusion, is seen[8]. The hypoperfusion zone seen
in subcutaneous tissue was greater then the one seen in
skeletal muscle at same pressure levels[8]. However, when
applying TNP to the myocardium, a significant, long-
standing zone of hypoperfusion could theoretically cause
ischemia, and negative effects on the myocardium. The
current study was designed to determine whether a zone
of relative hypoperfusion was produced during myocar-
dial TNP, as seen in subcutaneous and muscular tissue[8].
In the present study we show that, a TNP of -50 mmHg
applied over the LAD region significantly increases the
microvascular blood flow in normal myocardium, while a
TNP of -125 mmHg did not significantly alter the microv-
ascular blood flow. This indicates that no hypoperfusion
is produced in normal myocardium during TNP. In
ischemic myocardium, application of a TNP of -50 mmHg
over the LAD region resulted in a significant increase in
microvascular blood flow. However, a pressure of -125
mmHg did not induce any significant change in microvas-
cular blood flow in the ischemic myocardium. Conse-
quently, no hypoperfusion could be observed during
myocardial TNP in neither normal nor ischemic myocar-
dium. The absence of hypoperfusion might be explained
by the higher density of myocardium than skeletal muscle
and subcutaneous tissue.
Among patients with ischemic heart disease, some are not
suitable for current revascularization procedures such as
percutaneous coronary interventions (PCI) and CABG,
because of extensive and technically problematic coronary
lesions, i.e. refractory angina pectoris. The natural
response to myocardial ischemia is neovascularization.
This angiogenic process is a physiological attempt to limit
myocardial ischemia. Therapeutic angiogenesis, wherein
exogenous growth factors are administered to ischemic
tissue to enhance reperfusion, has been investigated as a
potential form of treatment for patients with advanced
coronary artery disease as an alternative to conventional
treatment such as PCI and CABG. VEGF proteins have
been shown to play a key role in the modulation of ang-
iogenesis and vascular growth [20,21]. Interestingly, TNP
produces a mechanical shear stress that is known to acti-
vate endogenous VEGF[25,26,31-33].
Conclusion
In conclusion, no hypoperfusion could be observed in the
epicardium in neither normal nor ischemic myocardium
during myocardial TNP. Myocardial TNP may in the
future, constitute an alternative therapeutic intervention
to stimulate blood flow in the failing myocardium in
patients with ischemic heart disease.
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